BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 14734732)

  • 1. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response.
    Meazza R; Lollini PL; Nanni P; De Giovanni C; Gaggero A; Comes A; Cilli M; Di Carlo E; Ferrini S; Musiani P
    Int J Cancer; 2000 Aug; 87(4):574-81. PubMed ID: 10918200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
    Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
    J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).
    Park JW; Gruys ME; McCormick K; Lee JK; Subleski J; Wigginton JM; Fenton RG; Wang JM; Wiltrout RH
    J Immunol; 2001 Mar; 166(6):3763-70. PubMed ID: 11238618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
    Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
    J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
    Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
    Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
    Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
    J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2.
    Grosso JF; Herbert LM; Owen JL; Lopez DM
    J Immunol; 2004 Aug; 173(3):1721-30. PubMed ID: 15265901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
    Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J
    J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.